Veradermics, Incorporated share price logo

Veradermics, Incorporated

NYSE: MANE

Mid Cap

$124.39

-0.47

(-0.38%)

as on

Veradermics, Incorporated Stock Performance

as on November 20, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $121.91
    $128.69
    downward going graph

    1.99%

    Downside

    3.46%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    downward going graph

    100.00%

    Downside

    -100.00%

    Upside

    downward going graph

Veradermics, Incorporated share price movements today

Previous Close
$124.86
Open
$126.55
Volume
206.5K
Market Cap
$5.3B
Day's Low - High
$121.91 - $128.69

Veradermics, Incorporated Historical Returns

1 Month Return
-2.14 %
3 Month Return
+ 18.11 %
1 Year Return
0 %
3 Year Return
0 %
5 Year Return
0 %

Veradermics, Incorporated Stock Fundamentals & Key Indicators

Check Veradermics, Incorporated market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$5.3B

EPS (TTM)

-2.64

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-47.3

Industry PE ratio

-14.19

PEG Ratio

1.23

EBITDA

-99.1M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-19.90%

Veradermics, Incorporated vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Veradermics, Incorporated with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Buy$5.3BNA-47.300.00%0.00%
Neutral$79.6B-24.43%-27.8028.00%0.00%
StrongBuy$46.1BNA65.3588.39%0.00%
StrongBuy$136.0B184.70%34.2685.53%0.00%
Buy$97.8B41.47%20.1385.77%0.39%

Analyst Recommendation on Veradermics, Incorporated Stock

Based on 2 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 2 analysts, 100% of analysts recommend a 'BUY' rating for Veradermics, Incorporated. Average target price of $180

Veradermics, Incorporated Share Price Target

Get share price movements and forecasts by analysts on Veradermics, Incorporated.

Current Price

$124.39

Analyzed by

2 Analysts

High

$185

0

Low

$175

Veradermics, Incorporated target price $0, a slight upside of 0% compared to current price of $124.39. According to 2 analysts rating.

Indian Investors' Interest in Veradermics, Incorporated Stock

Search interest for Veradermics, Incorporated Stock has increased by 13% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:13% versus previous 30 day period

Veradermics, Incorporated Quarterly Profit & Loss

All numbers in Millions USD

Dec 2024
Mar 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Total Revenue
-
-
-
-
-
-
-
Gross Profit
-
-
-
-
-
-
-
Operating Income
-5
-12
-20
-23
-29
-29
-28
EBITDA
-5
-12
-19
-21
-27
-29
-20
Interest Expense
0
-
-
0
-
-
-
Depreciation
-
-
-
-
-
-
-
Income Before Tax
-5
-12
-20
-21
-27
-23
-20
Income Tax Expense
-
-
-
-
-
-
-
Net Income
-5
-12
-20
-21
-27
-23
-20
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Veradermics, Incorporated Annual Profit & Loss

All numbers in Millions USD

Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
Gross Profit
-
-
-
Operating Income
-17
-26
-72
EBITDA
-16
-25
-69
Interest Expense
0
0
-
Depreciation
-
-
-
Income Before Tax
-16
-26
-69
Income Tax Expense
-
-
-
Net Income
-16
-26
-69
Net Profit Margin
0.00%
0.00%
0.00%

Veradermics, Incorporated Quarterly Cash Flow

All numbers in Millions USD

Dec 2024
Mar 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Net Income
-5
-12
-20
-21
-27
-23
-20
Operating Cash Flow
-3
-13
-19
-23
-21
-14
-22
Investing Cash Flow
-
-15
15
-109
-101
-277
-165
Financing Cash Flow
50
8
1
149
269
442
1
Change in Cash
46
-20
-2
16
146
150
-187

Veradermics, Incorporated Annual Cash Flow

All numbers in Millions USD

Dec 2023
Dec 2024
Dec 2025
Net Income
-16
-26
-69
Operating Cash Flow
-13
-23
-71
Investing Cash Flow
-
-
-118
Financing Cash Flow
13
60
159
Change in Cash
0
36
-31

Global Institutional Holdings in Veradermics, Incorporated

Check out the Institutions with significant holdings in Veradermics, Incorporated.

Funds
Holdings
Shares Held
John Childs
4.98%
2102006
BlackRock, Inc.
4.57%
1929832
Patrick Enright
4.27%
1803474
Longitude Capital Partners V, LLC
4.27%
1803474
Andreas Halvorsen
3.70%
1561494

Veradermics, Incorporated News & Key Events

  • img

    Today's Timeline - 09 November

    Mon, 05:56 PM

    -

    Veradermics reports positive topline results from Phase 2/3 trial of VDPHL01 for hair loss, showing significant hair count increases.

Insights on Veradermics, Incorporated

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, MANE stock has moved up by 18.1%

About Veradermics, Incorporated

Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
OrganisationVeradermics, Incorporated
Headquarters470 James Street, New Haven, CT, 06513, US
IndustryBiotechnology
CEOReid Waldman

Key Management of Veradermics, Incorporated

Name

Title

Mr. Mark Neumann

Chief Commercial & Strategy Officer

Dr. David A. Hollander M.B.A., M.D.

Chief R&D Officer

Dr. Reid Waldman M.D.

CEO & Director

Mr. Dominic Carrano CPA

CFO & Treasurer

Dr. Timothy Durso M.D.

Chief Technical Officer

Mr. Michael V. Greco J.D.

General Counsel & Secretary

FAQs

What is Veradermics, Incorporated share price today?

Veradermics, Incorporated share price today is $124.39 as on at the close of the market. Veradermics, Incorporated share today touched a day high of $128.69 and a low of $121.91.

What is the 52 week high and 52 week low for Veradermics, Incorporated share?

Veradermics, Incorporated share touched a 52 week high of $0.00 on and a 52 week low of $0.00 on . Veradermics, Incorporated stock price today i.e. is closed at $124.39,which is -Infinity% down from its 52 week high and Infinity% up from its 52 week low.

What is Veradermics, Incorporated's market capitalisation today?

Veradermics, Incorporated market capitalisation is $0.01T as on .

How to invest in Veradermics, Incorporated Stock (MANE) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Veradermics, Incorporated on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Veradermics, Incorporated Stock (MANE) from India?

Indian investors can start investing in Veradermics, Incorporated (MANE) shares with as little as ₹93.29000091552734 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹932.90 in Veradermics, Incorporated stock (as per the Rupee-Dollar exchange rate as on ). Based on Veradermics, Incorporated share’s latest price of $124.39 as on November 20, 2026 at 8:45 am IST, you will get 0.0804 shares of Veradermics, Incorporated. Learn more about fractional shares .